Francesco Fontana1, Silvia Cazzato2,3, Francesco Giaroni4,3, Fabrizio Bertolini3, Gaetano Alfano4, Giacomo Mori4, Silvia Giovanella3, Giulia Ligabue3, Riccardo Magistroni4,3, Gianni Cappelli3, Gabriele Donati4,3. 1. Nephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. francesco.fontana@unimore.it. 2. Nephrology and Dialysis Unit, Ospedale Ramazzini di Carpi, Azienda Unità Sanitaria Locale di Modena, Modena, Italy. 3. Surgical, Medical and Dental Department of Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy. 4. Nephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Abstract
BACKGROUND: Although discontinuation of antiplatelet agents at least 5 days before kidney biopsy is commonly recommended, the evidence behind this practice is of low level. Indeed, few non-randomized studies previously showed an equivalent risk of bleeding in patients receiving aspirin therapy. METHODS: We conducted a single center retrospective study comparing the risk of complications after percutaneous native kidney biopsy in patients who received low-dose aspirin (ASA) within 5 days from biopsy and those who did not. The main outcome was the difference in the incidence of major complications (red blood cell transfusion, need for selective arterial embolization, surgery, nephrectomy). Secondary outcomes included difference in minor complications, comparison between patients who received ASA within 48 h or within 3-5 days, identification of independent factors predictive of major complications. RESULTS: We analyzed data on 750 patients, of whom 94 received ASA within 5 days from biopsy. There were no significant differences in the proportion of major complications in patients receiving or not receiving ASA (2.59% and 3.19%, respectively, percentage point difference 1%, 95% CI - 3 to 4%, p = 0.74). Groups were also comparable for minor complications; among patients receiving ASA, there were no differences in major bleeding between those who received ASA within 48 h or 3-5 days from biopsy. Significant baseline predictors of major bleeding in our cohort were platelet count lower than 120*103/microliter, higher diastolic blood pressure and higher blood urea. CONCLUSIONS: Treatment with low-dose ASA within 5 days from kidney biopsy did not increase the risk of complications after the procedure.
BACKGROUND: Although discontinuation of antiplatelet agents at least 5 days before kidney biopsy is commonly recommended, the evidence behind this practice is of low level. Indeed, few non-randomized studies previously showed an equivalent risk of bleeding in patients receiving aspirin therapy. METHODS: We conducted a single center retrospective study comparing the risk of complications after percutaneous native kidney biopsy in patients who received low-dose aspirin (ASA) within 5 days from biopsy and those who did not. The main outcome was the difference in the incidence of major complications (red blood cell transfusion, need for selective arterial embolization, surgery, nephrectomy). Secondary outcomes included difference in minor complications, comparison between patients who received ASA within 48 h or within 3-5 days, identification of independent factors predictive of major complications. RESULTS: We analyzed data on 750 patients, of whom 94 received ASA within 5 days from biopsy. There were no significant differences in the proportion of major complications in patients receiving or not receiving ASA (2.59% and 3.19%, respectively, percentage point difference 1%, 95% CI - 3 to 4%, p = 0.74). Groups were also comparable for minor complications; among patients receiving ASA, there were no differences in major bleeding between those who received ASA within 48 h or 3-5 days from biopsy. Significant baseline predictors of major bleeding in our cohort were platelet count lower than 120*103/microliter, higher diastolic blood pressure and higher blood urea. CONCLUSIONS: Treatment with low-dose ASA within 5 days from kidney biopsy did not increase the risk of complications after the procedure.
Authors: Vinayak Kumar; Matthew D Mitchell; Craig A Umscheid; Jeffrey S Berns; Jonathan J Hogan Journal: Clin Nephrol Date: 2018-02 Impact factor: 0.975
Authors: Giuseppe G L Biondi-Zoccai; Marzia Lotrionte; Pierfrancesco Agostoni; Antonio Abbate; Massimiliano Fusaro; Francesco Burzotta; Luca Testa; Imad Sheiban; Giuseppe Sangiorgi Journal: Eur Heart J Date: 2006-10-19 Impact factor: 29.983
Authors: Bruce Mackinnon; Emily Fraser; Keith Simpson; Jonathan G Fox; Colin Geddes Journal: Nephrol Dial Transplant Date: 2008-05-25 Impact factor: 5.992